A detailed history of Russell Investments Group, Ltd. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 77,701 shares of CRNX stock, worth $4.19 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
77,701
Previous 102,394 24.12%
Holding current value
$4.19 Million
Previous $4.59 Million 13.48%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$43.83 - $54.98 $1.08 Million - $1.36 Million
-24,693 Reduced 24.12%
77,701 $3.97 Million
Q2 2024

Aug 08, 2024

BUY
$42.12 - $51.91 $2.15 Million - $2.65 Million
51,060 Added 99.47%
102,394 $4.59 Million
Q1 2024

May 08, 2024

BUY
$34.76 - $46.81 $1.78 Million - $2.4 Million
51,320 Added 366571.44%
51,334 $2.4 Million
Q3 2023

Nov 13, 2023

BUY
$15.97 - $30.59 $223 - $428
14 New
14 $0
Q1 2022

May 05, 2022

SELL
$17.15 - $28.31 $14,457 - $23,865
-843 Closed
0 $0
Q4 2021

Jan 21, 2022

SELL
$19.35 - $28.41 $1.59 Million - $2.34 Million
-82,261 Reduced 98.99%
843 $23,000
Q3 2021

Nov 08, 2021

BUY
$16.88 - $25.23 $1.4 Million - $2.1 Million
83,104 New
83,104 $1.75 Million
Q2 2021

Aug 04, 2021

SELL
$15.9 - $21.15 $222,615 - $296,121
-14,001 Closed
0 $0
Q1 2021

May 10, 2021

BUY
$13.3 - $17.55 $53,452 - $70,533
4,019 Added 40.26%
14,001 $213,000
Q4 2020

Feb 08, 2021

BUY
$12.08 - $17.46 $106,086 - $153,333
8,782 Added 731.83%
9,982 $140,000
Q3 2020

Nov 09, 2020

SELL
$13.62 - $17.66 $59,928 - $77,704
-4,400 Reduced 78.57%
1,200 $18,000
Q2 2020

Aug 05, 2020

BUY
$13.04 - $23.23 $73,024 - $130,088
5,600 New
5,600 $98,000

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.9B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Russell Investments Group, Ltd. Portfolio

Follow Russell Investments Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.